Valeo Pharma Inc. (VPHIF)
OTCMKTS · Delayed Price · Currency is USD
0.000001
-0.000099 (-99.00%)
At close: Feb 11, 2026
Valeo Pharma Earnings Call Transcripts
Fiscal Year 2024
-
Q3 2024 revenues declined 11% year-over-year due to the loss of Xiidra, but core business grew 9% excluding Xiidra. Cost-saving measures improved adjusted EBITDA loss by 40%, and the company targets EBITDA positive in Q1 2025. REDESCA and respiratory units showed strong growth.
-
Q2 2024 saw record revenues and continued growth in core brands, despite a higher net loss driven by product mix and Xiidra's exit. Major restructuring aims to cut costs and support EBITDA breakeven by year-end, with strong momentum in respiratory and hospital segments.